Antibiotic use in dairy herds in the Netherlands from 2005 to 2012  by Kuipers, A. et al.
1632
J. Dairy Sci. 99:1632–1648
http://dx.doi.org/10.3168/jds.2014-8428
© 2016, THE AUTHORS. Published by FASS and Elsevier Inc. on behalf  
of the American Dairy Science Association®
ABSTRACT
The aim of this study was to examine the variation 
in antibiotic use and the effects of external factors on 
trends in antibiotic use at the herd level by using the 
number of daily dosages as an indicator for antibiotic 
use. For this purpose, antibiotic use was analyzed in 
94 dairy herds in the Netherlands from 2005 to 2012. 
The herds were divided into 3 groups of farmers: one 
group was guided in their antibiotic use from 2008 to 
2010 as part of the project, whereas the other 2 groups 
were not actively guided. The farms were located in 
10 of the 12 provinces and were clients of 32 of the 
300 veterinary practices that treat cattle. Sales invoices 
from the veterinary practices provided the antibiotic 
and cost data for the participating farmers. The num-
ber of animal-defined daily dosages (ADDD) indicates 
the number of days per year that the average cow in a 
herd is given antibiotic treatment. The average ADDD 
for all farms from 2005 to 2012 was 5.86 (standard 
deviation = 2.14); 68% of ADDD were used for udder 
health, 24% for clinical mastitis and 44% for dry-cow 
therapy. Variation in ADDD among herds decreased 
during the study period. The trend in ADDD can be 
described as having 3 phases: (1) a period of increasing 
use coinciding with little public concern about antibi-
otic use (2005–2007), (2) a period of growing awareness 
and stabilization of use (2007–2010), and (3) a period 
of decreasing use coinciding with increasing societal 
concerns (2010–2012). The greatest reduction in use 
was for drugs other than those used to treat the udder. 
Drug use for mastitis treatment fell considerably in the 
final year of the study period, whereas farmers were re-
luctant to reduce use for dry-cow therapy. Almost 40% 
of the herds were given less than 2.5 ADDD for dry-cow 
therapy, which is equivalent to 2.5 tubes per average 
cow in the herd, and 20% used more than 3 tubes per 
cow. Use of third- and fourth-generation cephalosporins 
and fluoroquinolones dropped from 18% of ADDD dur-
ing 2005 to 2010 to 1% in 2012, with a shift toward 
penicillins and broad spectrum drugs. The ADDD was 
22% lower in 2012 than 2007, the year of the highest 
usage. The decrease in ADDD over time varied between 
the 3 groups of farmers. During the second phase of 
the study, the guided group began to display a reduc-
tion in use, whereas the other groups only displayed a 
significant reduction in the third phase. The reduction 
in antibiotic use has resulted in lower veterinary costs 
per cow in recent years.
Key words: antibiotic use, variation and trend, dairy 
farmer group, treatment category
INTRODUCTION
An increase in the resistance of bacteria to antibiot-
ics, as observed in hospitals, is causing concern among 
medical practitioners (Schwarz et al., 2001; EFSA, 
2009, 2011). The use of antibiotics in animal produc-
tion is blamed for contributing to the increasing bacte-
rial resistance to antibiotics in humans (Wise et al., 
1998; Refsdal, 2000; Oliver et al., 2011). Leverstein-van 
Hall et al. (2011) have shown that bacteria in human 
patients, retail chicken meat, and live poultry share the 
same extended spectrum β-lactamases (ESBL) genes 
and plasmids. Likewise, Reist et al. (2013) and Timofte 
et al. (2014) reported the presence of ESBL in bacteria 
found in slaughtered cattle and milk from cows with 
mastitis. The European Food Safety Authority (EFSA, 
2009) has reported on the presence of methicillin-
resistant Staphylococcus aureus (MRSA) in livestock. 
Brunton et al. (2012) linked the high prevalence of 
cefotaximase-producing Escherichia coli in dairy calves 
to the selective pressure induced by the high level of 
antimicrobial residues in the waste milk fed to calves.
Grave et al. (2010) compared the sales of veterinary 
antimicrobial agents across 10 European countries in 
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2007 based on the total amount of active substances 
used in all animal sectors. Use of these agents in the 
Netherlands was reported to be relatively high. The 
European Food Safety Authority panel on Biologi-
cal Hazards (EFSA, 2011) concluded that “a highly 
effective control option would be to stop all uses of 
cephalosporins, systemically active third- and fourth-
generation cephalosporins, or to restrict their use; as 
co-resistance is an important issue, it is also of high 
priority to decrease total antimicrobial use in animal 
production in the European Union.”
In the Netherlands, societal and political debate 
on antibiotic use has intensified since 2008, following 
a consumer survey showing that information on food 
safety (e.g., contaminants and medicines) ranked high-
est among consumer demands (Verhees et al. 2008). The 
discovery of livestock-associated MRSA in hospitalized 
Dutch patients (van der Zee et al., 2013) and the detec-
tion of the same strains of ESBL in the livestock chain 
and humans (Leverstein-van Hall et al., 2011; Dierikx 
et al., 2013) have also fueled public debate.
A Memorandum of Understanding was signed in 
December 2008 between the Netherlands Ministry 
of Agriculture, Nature and Fisheries, the Ministry of 
Public Health, animal sector representatives and the 
Veterinary Association to monitor antibiotic use in 
the cattle, pig, and poultry sectors and develop use-
reduction strategies. The targets, which included a 20% 
overall reduction by 2011, increasing to a 50% reduc-
tion by 2013 with 2009 as a base year, were added 
to the Memorandum in 2010. Since 2011, actions to 
raise awareness of antibiotic use have been undertaken 
by farmers’ organizations, the Veterinary Association 
and Veterinary Practices, and the Dairy Processing 
Cooperatives and Companies. The preventive use of 
antibiotics, including dry-cow therapy, has come un-
der scrutiny. In January 2012, the use of third- and 
fourth-generation cephalosporins and fluoroquinolones 
was prohibited unless, following a herd examination, 
a veterinarian substantiates that no alternative drug 
is available for the treatment of the particular health 
problem.
Several studies have discussed antibiotic use in tra-
ditional and organic dairy farms (Zwald et al., 2004; 
Sato et al., 2005; Bennedsgaard, et al., 2010); a litera-
ture overview on antibiotic use was reported by Van 
Werven et al. (2012). Overviews of the use of active 
substances and treatments in 1,013 herds in major US 
dairy states were presented by Hill et al. (2009). Pol 
and Ruegg (2007) developed a method of quantifying 
drug usage and treatment practices, using the number 
of defined daily dosages per adult cow per year, provid-
ing insight into antibiotic use on 20 traditional and 20 
organic farms in Wisconsin. The same indicator was 
used by Saini et al. (2012), who estimated drug use in 
89 Canadian herds.
However, studies on antibiotic use at the herd level 
are rather limited, illustrating that antibiotic use is 
an emerging topic. Insight into the methods of antibi-
otic use and use-reduction strategies would be useful 
in guiding such a trajectory. Until now, knowledge of 
the effects of policy initiatives and public opinion on 
changes in antibiotic use in dairy herds has been scarce. 
In the studies that have been published, an examina-
tion of trends over time was not feasible due to the 
short duration of the studies.
Discussions in 2004 and 2005 among dairy stake-
holders in the Netherlands recognized the necessity of 
improving the use of veterinary medicine data (Kuipers 
et al., 2005a). A pilot study was undertaken to examine 
the data collection and identify useful indicators for 
monitoring medicine use in dairy herds. Subsequently, 
data on antibiotic use were collected from a group of 
dairy farms over an 8-yr period. Against this back-
ground, the objectives of our study were to examine 
the variation in antibiotic use over time with the effects 
of selected external factors on the trends in antibiotic 
use at the herd level.
MATERIALS AND METHODS
Source of Data
Data on drug use were collected in a group of 94 
dairy farms in the Netherlands from 2005 to 2012 as 
part of two consecutive projects on medicine use. These 
data, together with experiences recorded during the 
same period, provided the source material for the pres-
ent study.
Sales of drugs to farmers are facilitated by veterinary 
practices and recorded in their management adminis-
tration system. Additionally, drugs used by veterinar-
ians during farm visits and the number of hours the 
veterinarian spent on the farm are also recorded daily in 
the management administration system. Each month, 
invoices are prepared and sent to the farmers based 
on the recorded data. The farmers participating in the 
study signed an agreement permitting the project team 
to collect detailed drug usage data from these invoices 
from the veterinary practices. Initially, some farmers 
also purchased small quantities of drugs through online 
veterinary services. Where this occurred, the invoices 
were copied from the farm records, but this practice 
ceased during the course of the project. The invoices 
list the brand names, quantities, and costs of the drugs 
and other materials alongside costs (professional fees) 
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for the farm visits by the veterinarian. Drugs contain-
ing antimicrobial ingredients were selected as input 
for this study. In addition, the number of teat sealer 
injectors together with the cost of drugs, materials, and 
veterinary fees were recorded from the invoices. The 
accumulated yearly veterinary costs per farm (€) were 
used as input for this study. The cost data for the whole 
study period were available for a subset of 45 of the 94 
farms.
Farmer Groups
The farmers involved in this study belonged to 1 of 
the following 3 groups:
 1. Guided group of farmers (41). This group com-
prised 6 subgroups of 6 to 8 farmers each from 
different veterinary practices. In each veterinary 
practice, one veterinarian was assigned as the 
local contact person. Early in 2008, the farm-
ers were recruited by these veterinarians in co-
operation with the project team. The aim was 
to recruit a group of dairy farms that varied in 
terms of herd size and farmer age. One of the 
recruited farmers stopped farming during the 
project period, and this farmer’s data were ex-
cluded from the analysis. The farms were located 
in 6 provinces along the north–south axis of the 
Netherlands, including all of the intensive dairy 
farming provinces. This group of farmers was 
actively guided in antibiotic usage in 2008, 2009, 
and 2010 by the project team. The local vet-
erinarian contact and 2 project team members 
organized and attended the subgroup meetings 
twice a year. During these meetings, antibiotic 
use and trends from 2005 onward were discussed 
and compared and overviews of antibiotic use of 
all guided subgroups were provided. The efficien-
cy of data collection, policy developments, and 
expert reports on antibiotics-related issues were 
also discussed. In 2011 and 2012, the reports on 
antibiotic usage in 2010 and 2011, respectively, 
were emailed to these farmers without discus-
sion.
 2. Incidental group of farmers (40). These farmers 
joined the study in 2008 and 2009 at the request 
of the project team following contact during 
meetings or otherwise. The aim was to identify 
a group of dairy farms that varied in terms of 
herd size and age of farmers. Two of these farm-
ers stopped farming during the project period 
and their data were excluded from the analysis. 
The farmers were associated with 17 different 
veterinary practices, 4 of which also had farmers 
in the guided group. The farms were located in 
9 of the 12 provinces. No feedback was provided 
until 2011, which is when the antibiotic usage 
for 2005 through 2010 was reported to them by 
e-mail. The data for 2011 were also reported by 
e-mail in 2012.
 3. Environmental group of farmers (13). This group 
of farmers consisted of participants in a long-
term project on farm nutrient management (Kui-
pers et al. 2005b). They were associated with 13 
veterinary practices, which are all different from 
those involved with the other 2 groups, and were 
located in 9 of the 12 provinces. Antibiotic use 
was not a topic that was addressed in this group 
until the project team calculated the number of 
daily dosages used in 2011 on each farm. The 
results were presented to the farmers in 2012.
Antibiotics Indicator
Animal-defined daily dosages (ADDD) were used 
as an indicator of antibiotic use (Jensen et al., 2004; 
Bondt et al., 2013; WHO, 2014). When applying this 
indicator to dairy cows, the number of daily dosages 
indicates how many days per year an average cow in 
the herd is treated with antibiotics. The average cow 
weight was set at 600 kg, and each tube used for dry-
cow therapy was counted as one daily dose. Antibiot-
ics administered to young stock were included in the 
calculation of the number of daily dosages per average 
cow in the herd. Sprays for claw and skin treatments 
were excluded. The calculations were performed in ac-
cordance with the national standard calculation. The 
number of ADDD (Bos et al., 2013) per cow in year t 
and herd h was calculated as follows:
 ADDDth
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i
n
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B ADD
C
=
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=
∑ /
,1   [1]
where n = number of drugs i involved in analysis (i.e., 
65, including the category of other drugs); Bi = the 
amount of drug i bought by or sold to herd h in year t 
in milliliters, tubes, or grams; ADDi denotes the animal 
(cow) defined daily dosage of drug i measured in mil-
liliters, tubes, or grams; when drug i was used in calves, 
the ADDi was multiplied by the factor 0.1 to adjust for 
the average weight of a cow; and Cth is the number of 
cows present, on average, during year t in herd h. The 
total usage in year t was 
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Antibiotic Treatment Categories
The drugs used were grouped under specific treat-
ments. The treatment categories were classified as 
tubes for dry-cow therapy, drugs for mastitis, pills for 
retained placenta (postparturient), drugs for reproduc-
tion (metritis), and oral powders for calves. The remain-
ing drugs, together with any incidentally used drugs, 
were assigned to a category of other drugs. Thereafter, 
ADDD were calculated per treatment category.
The number of daily dosages (tubes) per cow per year 
that were used for dry-cow therapy (ADDDdry-cow) is 
an important criterion, which depends on the farmer’s 
policy toward dry-cow therapy and several herd charac-
teristics. This can be expressed as follows:
ADDD
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where PC = percentage of cows remaining in a herd 
that receives dry-cow therapy (all teats); CI = calving 
interval of the herd (days); PR = percentage of cows 
replaced; and PTT = percentage of cows that have 3 
teats instead of 4.
Currently, 3 classes of drugs are specified in veteri-
nary practices in the Netherlands: first-choice drugs are 
advised; second-choice drugs are permitted; and third-
choice drugs are restricted for use and, as of January 1, 
2012, may only be used by veterinarians (Royal Dutch 
Veterinary Association, 2013). Because the brand 
names of drugs are not universally recognized, the 
brand names were substituted with the corresponding 
therapeutic groups (combinations of active substances), 
whereas the class of drugs to which the active sub-
stances belong was also indicated. The ADDD for the 
various groups of active substances were calculated and 
expressed as percentages of total use.
Analysis of Variation and Trends
This was a descriptive study similar to that indicated 
by Hicks and Turner (1999) as ex post facto research, 
which describes variation and trends in antibiotic data 
over time. Moreover, we searched, in retrospect, for fac-
tors that influence changes in variation and trends.
The farm was taken as the observational unit, and 
the average ADDD per cow per year was calculated for 
the period from 2005 to 2012. Most herds were served 
by different veterinarians. This implies a confounding 
of the effect of the veterinarian and farm or farmer. 
However, the 6 guided farmer groups each had a single 
veterinarian, other than their regular veterinarians, as 
part of the supporting team that guided that particular 
subgroup of herds. The influence of this veterinarian 
can be seen as part of the external effect of guidance.
Some of the drug data for the 94 farms were missing 
from 2005 to 2007 (data for 14 farms missing in 2005, 
7 in 2006, and 3 in 2007), which was due to adminis-
trative problems in retrieving the invoices from some 
of the veterinary practices in these years. To establish 
whether these missing data caused bias, a 2-sample t-
test was used to test the equality of means, and the 
Satterthwaite method was used to test the equality of 
variances. Means and variances from 2008 to 2012 for 
the farms with missing values in 2005 to 2007 were com-
pared with the farms with complete data sets. The null 
hypothesis stated that both groups of farms belonged 
to the same farm population, which was performed for 
the 3 separate farmer groups. The ADDD means for 
the farms with missing values or complete data sets 
within the 3 farmer groups did not differ significantly 
for any year within the period of 2008 to 2012, and the 
only difference in variances was observed for the guided 
group in 2010 and the environmental group in 2011. 
Therefore, it was concluded that there was no indica-
tion of bias due to missing values.
In the first part of the statistical analysis, the varia-
tion and trend in daily dosages per cow per year were 
analyzed for individual herds. Farm levels of antibiotic 
use (herdi) were regressed against time (in years), pro-
viding a mean (mi) and a trend (bi = regression coeffi-
cient). To illustrate changes in antibiotic use, the mean 
level of use (mi) for each individual farm during the 
first period of the study (2005 to 2010) was compared 
with that of the last period (2010 to 2012), whereas 
the regression coefficients for each farm (bi) from 2005 
to 2010 and 2010 to 2012, respectively, were used to 
demonstrate the trends in use during these periods.
The distribution of ADDD was characterized by the 
median, standard deviation, skewness, and kurtosis 
statistics. To establish between-year fluctuations in 
ADDD, a Pearson correlation was computed between 
the individual ADDD of the herds in 2 consecutive 
years. The calculations were performed in Microsoft 
Excel 2010 (Microsoft Corp., Redmond, WA). Statisti-
cal significance was determined at the 1 and 5% prob-
ability levels.
In the second part of the analysis, variation and 
trends in daily dosages were analyzed according to 
farmer group and antibiotic treatment category. Analy-
ses of variance were performed to test the effects of the 
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farmer group, year, and interaction using the ANOVA 
procedure of SPSS ver. 19 (IBM Corp., Armonk, NY). 
Farms were clustered within groups and measured over 
the years of 2005 to 2012. Observations from the same 
farm for different years are not independent, so the 
repeated measurement procedure was used. Multiple 
comparisons between group means and year means 
were computed using the Bonferroni test.
Trends in the ADDD for both the farmer groups 
and antibiotic treatment categories were evaluated by 
a regression against time (years). Because of external 
factors influencing the level of antibiotic use, 3 time 
phases were selected to reflect the changing trends over 
time (i.e., the periods 2005 to 2007, 2007 to 2010, and 
2010 to 2012). The trends in the ADDD within each 
time phase (t) and treatment category or farmer group 
(g) were characterized by a regression coefficient (bgt), 
which was derived as the average of the regression coef-
ficient (bi) of the individual farms. Within each farmer 
group and antibiotic treatment category, significant 
increases or decreases in use per time phase or combi-
nation of time phases were determined using a paired 
t-test. In addition, the relationship between ADDD val-
ues and yearly veterinary costs over time was examined 
using the Pearson correlation for the subset of herds. 
Significance was set at the 1 and 5% probability levels, 
and calculations were performed using SPSS. Farmers 
were questioned about their antibiotic use practices 
during the guided farmer group sessions.
RESULTS
The group of 94 dairy farms was spread through-
out the country and linked to 32 of approximately 300 
veterinary practices that treat farm livestock. In 2012, 
the dairy sector in the Netherlands comprised 18,682 
herds with an average herd size of 79 cows. The guided, 
incidental, and environmental farmer groups had aver-
age herd sizes of 110 (range = 46–309), 107 (36–437), 
and 130 (96–189) cows, respectively. The average age 
of the farmer upon joining the project was 43 yr (range 
= 24–62).
Changes in Antibiotic Use on Individual Farms
Changes in antibiotic use between the first and last 
phases of the study period are illustrated in Figure 1, 
where the ADDD for each farm is summarized by the 
mean and regression coefficient against time. The low-
est ADDD was 0.37 and the highest was 16.6. The dis-
tribution of ADDD was skewed toward higher values (n 
= 728; mean = 5.86; median = 5.55; Skewness = 0.87 
and Kurtosis = 1.59, both significant at P < 0.01). The 
farms were plotted on a graph comprising 4 quadrants 
that indicate above or below average and increasing 
or decreasing trends. In the period from 2005 to 2010 
(Figure 1a), the farms were mostly positioned in the 
above average and increasing trend quadrants, whereas 
during the 2010 to 2012 period (Figure 1b) half of the 
farms were identified as below average with decreasing 
trends.
Between-year (Pearson) correlations of ADDD for all 
herds are listed in Table 1; all correlations were statisti-
cally significant (P < 0.01). The correlations between 
consecutive years were highest, ranging from 0.53 to 
0.70, indicating that 28 to 49% of the variation in any 
year was explained by the situation in the previous year. 
One exception was 2012, when ADDD were observed to 
be slightly more dependent on ADDD in 2010 than in 
2011. This was caused by a very different trend in use 
reduction among the 3 farmer groups in 2011 and 2012. 
The fact that more than half of the variation in daily 
dosages per cow per herd in a particular year cannot be 
explained by the previous year indicates considerable 
fluctuation in ADDD between consecutive years.
Variation and Trends in Farmer Groups
Variation Between Farmer Groups and Years. 
The ANOVA statistics for 2005 to 2012 for the total 
group of farmers (94) and each of the 3 farmer groups 
are presented in Table 2. Missing values in the initial 
years did not significantly affect the analysis. The 
overall mean and standard deviation were 5.86 and 
2.14 ADDD, respectively. The main effects of group 
(P = 0.001) and year (P = 0.04) were both significant, 
but no significant interaction was found between these 
effects, indicating that the trend over the years was 
consistent across the groups. Both the guided and en-
vironmental groups had significantly lower ADDD than 
the incidental group. In addition, the ADDD for 2012 
was significantly lower than the values from 2007 to 
2010.
The standard deviation and coefficient of variation of 
the ADDD decreased from 2.37 and 0.41, respectively, 
in 2005 and 2006 to 1.64 and 0.33, respectively, in 2012, 
which illustrates a reduction in variation toward the 
end of the study. The average ADDD of the guided 
subgroups varied from 3.17 to 6.75 (SD = 1.16) in 2005 
and 2006 and from 3.59 to 5.20 (SD = 0.72) in 2012, 
also indicating less variation over time.
Trends and Adaptation. The trends in the ADDD 
over the years for the 3 farmer groups are illustrated 
in Figure 2. These results are presented in 3 phases. 
During the first phase (2005 to 2007), farmers were still 
increasing antibiotic use when little societal concern for 
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Figure 1. (a) Number and trend of animal defined daily dosages per cow (ADDD) from 2005 to 2010 for each of the 94 herds. (b) Number 
and trend of ADDD from 2010 to 2012 for each of the 94 herds; b-coefficient is the number of ADDD regressed against time in ±ADDD per year.
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antibiotic use in animals was present. The second phase 
(2007 to 2010) was a period of growing public aware-
ness and the beginning of a reduction in antibiotic use 
by some farmers. Indeed, the group of farmers that 
was coached from 2008 onwards achieved a significant 
reduction in antibiotic use in this phase (Figure 2). 
The environmental group comprised participants who 
were already involved in a sustainability program but 
did not become actively acquainted with the antibiotic 
issue until 2012. Nevertheless, this group showed a very 
significant reduction in antibiotic use in 2011 during 
the reduction phase (2010 to 2012). A year later, in 
2012, the incidental farmers group observed a similar 
level of reduction in use.
Variation and Trends in Treatment Categories
Number of Daily Dosages per Treatment Cat-
egory. Approximately 98% of the antibiotic applica-
tions in ADDD were covered by 54 drugs. The drugs 
can be designated as specific treatments. In this study, 
there were 6 antibiotic treatment categories—mastitis, 
dry-cow therapy, calves, retained placenta, reproduc-
tive tract, and other. In total, 37 drugs were assigned 
to the first 5 treatment categories. The remaining drugs 
(17), together with any incidentally used drug, were 
assigned to the sixth category of other drugs. The 2 
main treatment categories were dry-cow therapy and 
mastitis, which are both related to udder health. These 
2 categories accounted for 68% of all ADDD in the 
period from 2005 to 2012—44% for dry-cow therapy 
and 24% for mastitis. Most of these treatments were 
administered through the intramammary route (63%), 
with only a small proportion (5%) administered sys-
temically for the treatment of clinical mastitis. Only a 
small proportion of the remaining ADDD were directly 
attributable to specific treatments, such as medication 
for young calves, retained placenta, and metritis (Table 
3). Most of the remaining drugs (assigned as other 
treatments) were used for a category of illnesses related 
Table 1. Pearson correlation coefficients1 between years for number of animal defined daily dosages (ADDD) 
per cow per herd from 2005 to 2012
Herd,  
n  Year 2006 2007 2008 2009 2010 2011 2012
80 2005 0.704 0.649 0.661 0.598 0.548 0.450 0.380
87 2006 1.000 0.683 0.625 0.471 0.461 0.445 0.387
91 2007  1.000 0.660 0.516 0.517 0.491 0.413
94 2008   1.000 0.651 0.549 0.506 0.402
94 2009    1.000 0.638 0.567 0.468
94 2010     1.000 0.635 0.595
94 2011      1.000 0.534
94 2012       1.000
1All correlations (r) deviate from zero (P < 0.01).
Table 2. Means and SD of number of daily dosages per cow for 3 farmer groups from 2005 to 2012
Year
Farmers study group
 
All study groups 
(n = 94)Guided (n = 41)
 
Incidental 
(n = 40)
 
Environmental 
(n = 13)
Mean SD Mean SD Mean SD Mean SD
20051 5.18 2.21  5.93 2.58  5.98 1.66  5.62 2.33
20061 5.65 1.96  6.48 2.84  5.27 1.88  5.97 2.40
20071 6.07 2.18  6.86 2.90  6.02 2.44  6.41v 2.55
2008 5.78 1.68  6.63 2.14  5.88 1.81  6.16v 1.93
2009 5.48 1.55  6.55 2.24  6.14 0.80  6.02v 1.87
2010 5.40 1.46  6.59 2.33  6.22 1.85  6.02v 1.99
2011 5.16 1.78  6.43 2.36  4.78 0.96  5.65 2.07
2012 4.86 1.63  5.21 1.73  4.84 1.44  5.00w 1.64
Total 5.45a 1.83  6.34b 2.43  5.63a 1.69  5.86 2.14
a,bMeans within the row “Total” with a different superscript differ (P < 0.05), according to the Bonferroni test.
v,wMeans within the column “All study groups” with a different superscript differ (P < 0.05), according to the 
Bonferroni test.
1In 2005, the Guided, Incidental, and Environmental groups comprised 35, 35, and 10 farms, respectively; in 
2006, the numbers were 39, 37, and 11 farms; in 2007, the numbers were 40, 39, and 12 farms; and from 2008 
to 2012, the numbers were 41, 40, and 13 farms.
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to claw ailments, respiratory tract infections, and diges-
tive tract problems. All drugs in these last categories 
were administered through the systemic route.
Variation and Trends. The lowest variation was 
observed in the use of dry-cow therapy tubes, whereas 
drug usage for calves and the reproductive tract varied 
considerably among herds (Table 3). The ADDD for 
dry-cow therapy did not correlate with the ADDD for 
mastitis and the remaining treatment categories over 
the 8-yr period (94 farms; n = 728), but the ADDD 
for the last 2 categories did correlate with each other 
(r = 0.44). The number of ADDD for mastitis and the 
remaining categories did explain most of the variation 
in total ADDD (r = 0.74 and 0.75, respectively). The 
number of ADDD for dry-cow therapy remained rather 
constant throughout the study period (at approximate-
ly 2.5 ADDD) and, consequently, displayed a relatively 
low correlation with total ADDD (r = 0.48).
The ANOVA analyses indicated no significant farmer-
group or year effect for ADDDdry-cow from 2005 to 2012. 
The ADDD for mastitis was subject to a farmer-group 
effect (incidental group > guided and environmental 
groups; P = 0.001 and P = 0.01, respectively), whereas 
ADDD for remaining categories displayed both a group 
and year effect (incidental group > guided group; P = 
0.001, and years 2007 and 2008 > 2012; P = 0.001). 
No significant interaction was found between the main 
effects.
The decreasing trend in total usage began in 2007 
(Figure 3). From that time onwards, regression coef-
ficients for the annual change in ADDD for dry-cow 
therapy, mastitis, and the remaining categories were 
−0.050, −0.054, and −0.140, respectively. Thus, the re-
duction in use for the remaining categories was almost 
triple that of dry-cow therapy or mastitis. The overall 
trend in use was influenced mostly by the reduction in 
use of categories other than udder-related treatments 
during the second (2007 to 2010) and third (2010 to 
2012) phases and a reduction in use for mastitis treat-
ments in the third phase, specifically in 2012. These 
decreases in ADDD were all significant (P < 0.01), ac-
cording to the paired t-test.
An overall reduction of 22% in ADDD was observed 
in 2012 compared with 2007, the year with highest 
average use in the farm sample (−17% compared with 
reference year 2009). Topical antibiotic applications 
(sprays in aerosols) were not included in the ADDD 
calculation. In this study, 83% of the farmers used these 
sprays for 1 or more years. Annually, between 0 and 24 
aerosols (210 mL) were purchased per farm. Average 
aerosol use per herd varied from 0.57 ADDD in 2005 
Figure 2. Trend in the number of daily dosages per cow per year for the 3 farmer groups for each of 3 time phases; significant within-group 
changes in each phase are indicated and expressed by the regression coefficient as ±animal defined daily dosages per cow (ADDD) per year. *P 
< 0.05, **P < 0.01, according to the paired t-test.
Table 3. Means, SD, and CV for the number of daily dosages per cow 
per year for 6 treatment categories, averaged over 8 yr and 94 farms
Treatment Mean SD CV
Mastitis 1.45 1.06 0.73
Dry-cow therapy 2.57 0.94 0.36
Calves 0.19 0.35 1.84
Retained placenta 0.11 0.14 1.28
Reproductive tract 0.05 0.08 1.63
Other 1.50 1.01 0.68
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and 2006 to 0.44 ADDD in 2011 and 2012, based on the 
assumption that each aerosol was used 10 times.
Dry-Cow Therapy Levels
Blanket dry-cow therapy, a replacement rate of 25%, 
a calving interval of 365 d, and all 4-teat cows result 
in an ADDDdry-cow value of 3 using equation [3]. A 
higher replacement rate (more heifers in the herd) and 
a longer calving interval would lower the ADDDdry-cow 
value. In the Netherlands, the average calving interval 
from 2005 to 2012 was 417 d, the replacement rate was 
28% (CRV, 2013), and 2% of the cows were assumed to 
have only 3 teats. These average statistics result in an 
ADDDdry-cow value of 2.5, implying that, on average, 2.5 
tubes per cow were used for blanket dry-cow therapy.
Additionally, for the study farms, the average 
ADDDdry-cow values (tubes) per farm were calculated 
for the period from 2005 to 2012. This indicated that 
17% of farms used less than 2 antibiotic tubes per cow, 
21% used 2.0 to 2.5, 41% used 2.5 to 3.0, 18% used 3.0 
to 3.5, and 3% of farms used more than 3.5 tubes per 
cow. Although it was expected that 2.5 tubes per cow 
were used for blanket dry-cow therapy, according to the 
above estimate based on the national data, it appeared 
that one-fifth of the study herds used 3 or more tubes 
per cow.
Active Substances per Treatment Category
The use of active substances in the periods of 2005 
to 2010 and 2011 to 2012 are presented in Table 4. 
These periods were selected because the regulations 
concerning third-choice drugs had been announced 
in 2011 and were introduced in 2012. In this study, 
active substances, such as amoxicillin-clavulanic acid 
and first- and second-generation cephalosporins-amino-
glycoside combinations, were used mostly for mastitis 
treatments; narrow-spectrum penicillins and procaine 
penicillin-aminoglycoside combinations were used for 
dry-cow therapy; and penicillin-aminoglycoside combi-
nations and tetracyclines were used for the remaining 
treatment categories (Table 4). The use of third-choice 
drugs (i.e., third- and fourth-generation cephalosporins 
and fluoroquinolones) was, on average, 18% of total us-
age during the 2005 to 2010 period. This number was 
reduced to 14.5% in 2011 and became minimal in 2012. 
The third-choice drugs were mainly used for mastitis 
and the remaining treatment categories such as claw 
diseases (Table 4).
Veterinary Cost and Teat Sealers
Veterinary costs per cow per year, including drug 
costs plus the fees for farm visits and guidance as as-
sessed in a subset of farms, increased until 2009 and 
then declined (Table 5). In both the first phase of the 
study period (2005 to 2007) and the combined second 
and third phases (2008 to 2012), veterinary costs cor-
related (highly) with, respectively, the increasing and 
decreasing trends in antibiotic use (r = 0.96 for both 
periods; P = 0.16 for first phase; P = 0.01 for second 
and third phases).
The percentage of farms using teat sealers increased 
from 8% in 2005 to 53% in 2012, and the average num-
ber of teat sealers per cow increased from 0.42 to 1.88 
Figure 3. Trend in the number of daily dosages per cow per year for 3 treatment categories and total usage for all farms from 2005 to 2012.
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in the same period within these herds (Table 5). The 
use of dry-off tubes did not decrease as teat sealer use 
increased. Consequently, the combination of dry-off 
tubes alongside teat sealers has become a more com-
mon dry-cow therapy practice.
DISCUSSION
Our study describes variations and trends in anti-
biotic use in commercial dairy herds during an 8-yr 
period, which makes this study rather unique because 
few such studies have been performed and almost no 
comparable data sets are available for analysis. Even 
so, the limitations of this data set did not enable us 
to explore the factors behind the variation and trends 
reported in detail. For instance, the lack of sufficient 
data impaired our ability to analyze the effect of herd 
health status on antibiotic use and, likewise, the in-
fluence of the veterinary practice (a large number of 
the farms were linked to different practices). Addition-
ally, the reactions of both farmers and veterinarians 
to the ongoing public debate on antibiotic use were 
not experimentally measured. Accordingly, some of our 
observations are based on field work with the guided 
and environmental groups rather than on data analysis.
In this section, particular attention is given to the 
collection and representativeness of the data to place 
the observed variation and trends of antibiotic use in a 
wider context. Finally, the role of increasing awareness 
in dealing with the antibiotic issue is discussed.
Collection and Reliability of Data
In 2005, at the beginning of our work on veterinary 
drug usage, we learned that drug data that were pre-
sented as standalone figures were not really of interest 
to farmers (Kuipers and Verhees, 2011). The data be-
came more interesting to the farmers after partitioning 
total use into treatment categories (e.g., how much of a 
particular drug is used to counteract various problems 
and diseases). Farmers were also interested in data per 
individual cow, as found with milk recording data, and 
how their drug usage compared with that of their fellow 
farmers. Cow health and drug data are stored on-farm 
in the farm management computer system. Data input 
is usually performed by the farmer, the farmer’s fam-
ily, or farm staff. The potential for use of these data 
for the present study was examined at an early stage. 
Data from the farm computers of the guided farmer 
group for the years 2005 to 2007 were downloaded onto 
the research database. It soon became apparent that 
the sales data obtained from the veterinary practices 
displayed similar or higher drug usage than the data 
obtained from the farm management computers; this 
was also observed by González et al. (2010). The in-
voices contain complete and reliable data, whereas da-
tabases relying solely on the farmer were occasionally 
incomplete. In addition, uniformity in record keeping 
is of the utmost importance in enabling comparisons 
between farms in the study groups. Various computer 
systems have different options available for data input, 
whereas, within a computer system, flexibility of input 
is possible, which complicates comparisons between 
farms. For these reasons, we decided not to use the 
farm-recorded data for our study and chose the data 
provided through veterinary sales invoices. However, 
the data from invoices are at the herd level, which may 
be considered a disadvantage. Nevertheless, working on 
an aggregated herd basis simplified the administration, 
calculations, and information material considerably. 
Drug information on a herd basis is comparable, for 
instance, to cell count data at the herd level, which 
both provide a global impression of antibiotic usage 
and the udder health status of the herd, respectively.
Indicator Daily Dosages
Available indicators for measuring antibiotic use 
include total active substances and number of daily 
dosages. Quantities of active substances sold are re-
ported by the drug retail companies but are not defined 
per animal species. These company reports provide a 
global indication of total antibiotic use at the national 
or regional level for policy purposes. On a herd basis, 
the amount (kg) of active substances has been used as 
indicator (Carson et al., 2008; Katholm, 2014). Carson 
et al. (2008) compared the indicators active substances 
and daily dosages in a study comprising 24 beef farms 
Table 5. Veterinary costs and teat sealer use from 2005 to 2012, average of herds
Item 2005 2006 2007 2008 2009 2010 2011 2012
Veterinary costs/per cow year1 (€) 70 74 76 83 84 84 81 77
Teat sealers in tubes per cow
 Average of all herds 0.03 0.05 0.20 0.49 0.59 0.64 0.89 1.00
 Average of herds using teat sealers 0.42 0.64 0.74 1.46 1.42 1.50 1.81 1.88
1Calculated on the basis of 45 farms.
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in Canada. They concluded that “the relative ranking 
of use of antimicrobials varied with the chosen metric, 
and that further investigation into the best measure in 
relation to antibiotic resistance is warranted.” Bondt 
et al. (2013) stated that “the ideal method for gaining 
insight into the true exposure to antimicrobial agents 
is to calculate the number of animal defined daily dos-
ages (ADDD) used per animal per year,” as is done 
in human pharmaco-epidemiology with the number of 
defined daily dosages per 1,000 inhabitant-days (WHO, 
2014). Animal-defined daily dosage is expressed as the 
average maintenance dose of a specified drug per kilo-
gram of live weight of a specified animal per day, which 
is used for its main indication (Jensen et al., 2004). On 
this basis, ADDD has been used as an indicator for 
antibiotic use in our study. However, it should be noted 
that ADDD only provides an estimate of the number 
of days of treatment on an annual basis (Y) by the 
average cow in the herd because the daily dose actually 
used may differ in practice from the defined daily dose 
(Chauvin et al., 2002; Carson et al., 2008; Merle et al., 
2014). Occasionally, a farmer or veterinarian may make 
his or her own interpretation of the best treatment to 
be applied (Trauffler et al., 2014).
The ADDD was calculated for a 600-kg cow, but the 
animal-defined dose is given on a per-kilogram basis, 
which facilitates precise administration to animals of 
different weights. This technique is especially impor-
tant in the pig and poultry sectors, where different live 
weight groups exist and calves require specific dose 
levels. Because the drugs used for young stock were not 
separated from those for cows, we included the drugs 
administered to young stock in the ADDD calculations 
for cows. Starting in 2012, all farmers in the Nether-
lands are required to submit their drug usage data to 
a central database for benchmarking purposes. This 
data collection (through veterinary practices) is orga-
nized by the sector, supported by public regulation. 
The newly founded Netherlands Veterinary Medicines 
Authority supervises the monitoring activities and sets 
benchmarks for national policy goals. Since 2013, the 
official calculations for dairy farms include the weight 
of young stock to that of cows (Netherlands Veterinary 
Medicines Authority, 2013). Consequently, data on the 
number of young stock per herd are collected and vet-
erinarians are directed to record which drugs are sold 
for young calves, which enables a separate calculation 
of ADDD for calves.
Sprays for claw and skin problems (i.e., topical ap-
plications) are not included in the ADDD calculations, 
which is similar to the practice in other European 
countries. Sprays were also not included in the study of 
Saini et al. (2012).
Representativeness
Potential biases may have caused the sample of 
study farms to deviate from the national population of 
farms with respect to antibiotic use. The fact that the 
farmers volunteered to participate in this project may 
suggest that drug use on these farms was somewhat 
lower than the national average. However, these farms 
were larger (111 cows) than the national average in 
2012 (79 cows per farm) and some reports (e.g., Hill et 
al., 2009) have indicated higher antibiotic use on larger 
farms. A separate analysis carried out on data from the 
present study, supplemented with questionnaire data 
relating to farm factors and farmer characteristics, did 
not detect a relationship between farm size and antibi-
otic use (Kuipers et al., 2013). Saini et al. (2012) also 
did not find such a relationship. Another factor that 
may have affected the level of antibiotic use is that 
organic farms were not included in the study sample. 
The number of organic dairy farms in the Netherlands 
is low (approximately 320; 1.7% of all dairy farms). 
Smolders (2010) reported that on 67 of these farms, 
the average antibiotic use was 1.9 ADDD from 2006 to 
2010. Based on this, the exclusion of organic farms may 
have had a small upward effect on the level of ADDD 
in the present study.
To gain more insight into the representativeness of 
the farm sample, the ADDD for the total group of farms 
were compared with the ADDD from the national Farm 
Accountancy Data Network (FADN) farms, which are 
selected to provide a representative sample of the na-
tional farm population. These farms are used by each 
European Union member state to report annually on 
economic and structural developments in agriculture. A 
proportion of the national FADN farms are replenished 
each year. The 31 FADN farms available throughout 
the period from 2005 to 2009 and the whole group of 
FADN farms (36 in 2005 increasing to 68 in 2012) had a 
level of antibiotic usage comparable to the study farms 
(Figure 4). However, the estimate of 4.2 ADDD for the 
FADN farms for 2012 is low compared with the previ-
ous year and the outcome for the total group of study 
farms (almost significant at the 5% level). Overall, the 
sample of farms appeared to provide a reasonable re-
flection of the antibiotic usage situation on dairy farms 
in the Netherlands.
Mean and Variation in Use
The mean and standard deviation of the ADDD over 
the 8 yr of the study were 5.86 and 2.14, respectively. 
Pol and Ruegg (2007) and Saini et al. (2012) reported 
ADDD mean values of 5.43 in Wisconsin herds and 
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5.24 in Canadian herds, respectively. The latter value 
was calculated by us converting 1,000 cow-day use to 
annual use. The comparisons are disputable because 
of different ways of collecting data, time periods, and 
potential differences in average live weight of cows be-
tween countries (or regions). Hill et al. (2009) and Pol 
and Ruegg (2007) based their data on a single survey 
covering periods of 12 mo and 5 yr (for intramammary 
dry-cow products) plus 2 yr (for the other drugs), re-
spectively. Saini et al. (2012) based their data on the 
collection of used drug injectors and containers by farm 
workers during a period of 23 mo. They also assumed, 
as in the present study, an average cow live weight of 
600 kg, whereas Pol and Ruegg (2007) worked with 
an average cow live weight of 680 kg. Moreover, the 
assignment of several daily defined dosages to drugs 
sometimes differs, especially for dry-cow therapy. For 
instance, in Canada (Saini et al., 2012) and Denmark 
(Katholm, 2014) one daily dose is assigned to blanket 
dry-cow therapy, whereas in the Netherlands 4 daily 
doses are assigned. When data from the Netherlands 
were recalculated on the basis of a single daily dose for 
blanket dry cow therapy, the mean use was 3.94 ADDD 
instead of 5.86.
Sales dates on veterinary invoices often do not coin-
cide with the on-farm application dates of the drugs. 
This is because farmers in the Netherlands are allowed 
to execute routine treatments themselves, and they may 
bulk purchase the drug in advance. For instance, teat 
injectors for dry-cow therapy are inserted by the herds-
man. These injectors are often purchased a few times 
per year in large quantities. As a consequence, on-farm 
ADDD may fluctuate considerably between years (even 
more so if expressed quarterly as was initially the case). 
Other possible causes of fluctuations include the health 
status of the herd and external factors that influence 
the farmer and veterinarian. Our data did not permit 
differentiation between these causes of variation. Na-
tionally, ADDD is calculated on a yearly basis and the 
Netherlands Veterinary Medicines Authority presents 
a rolling average. Although ADDD provides the best 
estimate for the most recent year, a 2-yr average or 
rolling average provides a more stable indicator for av-
erage herd antibiotic use, minimizing the effect of the 
purchasing behavior of the farmer on the level of use.
During the early years of our study, a large variation 
in ADDD was evident because farmers were unaware 
of the antibiotics situation on their farms (Kuipers 
et al., 2013). This was also experienced by Cabaret 
(2003). Variation in use decreased considerably during 
the later phases of the study period, which coincided 
with a growing political and public awareness, and the 
resulting sectoral activities related to antibiotic usage 
influenced the antibiotics usage behavior of both farm-
ers and veterinarians.
Antibiotic Treatment Categories
During 2005 to 2012, 68% of antibiotic use was used 
for udder health purposes, addressing the prevention 
of infections during the dry period, treatment of sub-
clinical mastitis at drying-off periods, and treatment of 
clinical mastitis (Table 3). This percentage was even 
higher in the study of Pol and Ruegg (2007), whereas 
Katholm (2014) also reported a value of 68% based 
on active substances. Taken together, these findings 
indicate that antibiotic use in dairy herds is largely an 
udder-related management practice. In our study, 63% 
of the total number of daily dosages was used via the 
intramammary route, whereas 37%, including oral pow-
ders for calves and intrauterine treatment, was used 
systemically. Pol and Ruegg (2007) reported similar 
percentages for intramammary and systemic use, but 
Saini et al. (2012) found higher systemic than intra-
mammary use. The Netherlands Veterinary Medicines 
Authority (2013) reported that the systemic route of 
administration accounted for 33% of the average anti-
biotic usage on all farms in 2012, similar to the level 
found in the current study (32% in 2012).
Figure 4. Comparison of trends in antibiotic use on the project 
farms, the total group of Farm Accountancy Data Network (FADN) 
farms (36 increasing to 68) in European Union member states from 
2005 to 2012, and a group of FADN farms (the same 31 farms) from 
2005 to 2009.
Journal of Dairy Science Vol. 99 No. 2, 2016
DAIRY INDUSTRY TODAY 1645
The lowest CV was found for ADDDdry-cow. About 
one-fifth of farms used less than 2 tubes per average 
cow in the herd and a similar proportion used more 
than 3 tubes per cow. This last observation merits fur-
ther examination because more than 1 tube per teat as 
dry-cow therapy would be considered excessive. During 
the guided farmer group sessions, it appeared that most 
farmers were reluctant to discuss the adaptation of 
blanket dry-cow therapy (Kuipers et al., 2013). System-
atic application of dry-cow therapy has been advocated 
by the veterinary profession in the Netherlands as a 
standard practice for the last 20 yr, as is the case in 
most dairy farming countries. An exception is Denmark, 
where only 40% of cows received dry-cow therapy in 
2009 when the average cell count was 235,300 cells/mL. 
Since 2010, Danish veterinarians have been required to 
examine a milk sample before prescribing drugs other 
than simple penicillin for mastitis treatment. This con-
strains the use of drugs during lactation and encour-
ages a shift toward curative dry-cow therapy. In 2013, 
when the national cell count was 212,100 cells/mL, 43% 
of cows received dry-cow therapy. The use of antibiotics 
tubes during lactation decreased by 48.5% from 2009 to 
2013, whereas the use of tubes for dry-cow therapy in-
creased by 13.4% in the same period (Katholm, 2014). 
McDougall (2012) reported that, in New Zealand, selec-
tive dry-cow therapy was used in about one-third of 
herds in 2011, whereas approximately 10% of cows and 
heifers were treated with a teat sealer. Selective dry-cow 
treatment was introduced in the Netherlands in 2014 as 
a recommended practice based on the individual cell 
count of cows before drying off (different levels apply 
for first lactation and older cows).
Active Substances
The use of third-choice drugs (i.e., third- and 
fourth-generation cephalosporins and fluoroquinolones) 
decreased from 18% of total usage from 2005 to 2010 
to 1% in 2012. In Australia, third-choice drugs were 
banned in the 1990s, whereas in New Zealand the usage 
is under restriction (McDougall, 2012). In Denmark, 
the restriction on third-choice lactation drugs, in force 
since 2010, has led to a decrease in the use of third- and 
fourth-generation cephalosporins, and almost no fluoro-
quinolones have been used since 2000 (Katholm, 2014).
The reduction in third-choice drugs in the present 
study was partly replaced by an increase in first- and 
second-choice drugs. For mastitis, a relative increase in 
cephalosporin combinations was observed; for drying-
off, an increase in procaine penicillin combinations was 
noted; and for other ailments, an increase in narrow-
spectrum penicillins and trimethoprim-sulfadoxine was 
recorded. Therefore, although a reduction in use of 
third-choice drugs occurred, there was also an increased 
use of penicillins and certain broad-spectrum drugs. Pol 
and Ruegg (2007) also reported the use of penicillins 
mostly for dry-cow therapy, whereas Saini et al. (2012) 
found that the most commonly used active substances 
in Canada, according to the level of use, were cepha-
losporins, penicillins, penicillin combinations, tetracy-
clines, trimethoprim-sulfonamide combinations, and 
lincosamides. However, the cephalosporins consisted 
mostly of third-generation drugs (especially ceftiofur).
Trends and Awareness
Trends in antibiotic use were presented in 3 phases. 
During the first phase (2005–2007), farmers were 
still increasing their antibiotic use. The second phase 
(2007–2010) saw the first signs of a reduction in anti-
biotic use by some farmers, and during the third phase 
(2010–2012) reductions became more apparent. Com-
munication with the guided group of farmers during the 
second phase, when external pressure on antibiotic use 
was still relatively low, was 2-fold: written information 
was sent to participating producers and regular study 
group meetings were held locally that involved produc-
ers, local contact veterinarians, and the project team. 
These actions were associated with a downward trend 
in antibiotic use. Raymond et al. (2006) observed a de-
creasing effect on medicated milk replacer use through 
information transfer by mail with farmers, whereas 
Jansen et al. (2010) described communication strate-
gies with farmers who were involved in an udder health 
improvement program and were hard to reach.
The environmental group of farmers were considered 
innovators with respect to the environment, but had 
not yet become engaged in the antibiotic issue. Nev-
ertheless, they seemed to react spontaneously to the 
public debate by reducing antibiotic use in 2011. In this 
context, the ongoing public discussion on third-choice 
drugs may also have affected their adaptation process. 
The incidental farmer group delayed change until 2012, 
when they responded, presumably, to societal and pro-
fessional pressure and the introduction of regulations 
in 2012 demanding minimal use of third-choice drugs. 
Lower drug costs per cow will be welcomed by farmers, 
but a restricted choice in drugs will be seen as a nega-
tive development.
It appears that adaptation was easier for mastitis 
and the other category drugs than for dry-cow therapy 
injectors. The stable application of dry-cow therapy 
over time was combined with an increase in the use 
of teat sealers. The recently introduced guidelines on 
selective dry-cow treatment create a complex trade-
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off between enabling farmers to reduce their antibiotic 
usage and limiting their ability to address cow health 
and welfare. Establishment of a final balance in antibi-
otic applications will take time. However, considerable 
variation exists in farm practices within and between 
dairy-producing countries that can provide helpful in-
formation. Moreover, future target levels for antibiotic 
use may be sharpened by governments depending on 
developments in antibiotic-resistant bacteria and soci-
etal pressure.
The combination of awareness-raising and restrictive 
measures appears to be effective in reducing antibiotic 
use (−17% in 2012 compared with 2009), although the 
contribution of the dairy sector to the national reduc-
tion goal (−50% by 2013) was modest. In comparison, 
large reductions in antibiotic sales of more than 50% 
have been achieved in the pig and poultry sectors 
within the same period (Mevius and Heederik, 2014).
The involvement of veterinary professionals is essen-
tial to achieve a change in the farmer’s usage behavior. 
In the Netherlands, the main communication tools 
between the veterinarian and farmer are the annual 
animal health and treatment plans. The animal health 
plan consists of a series of management and housing 
practices that may influence dairy cow health and, 
subsequently, drug usage. This plan provides a check 
list, whereas the treatment plan lists the most suit-
able drug per treatment category. These plans require 
regular consultation between veterinarians and farmers 
to manage specific animal health problems. Drug use 
awareness is facilitated by the appropriate presentation 
of data to farmers and veterinarians. Since 2012, farm-
ers have been informed of their ADDD on a quarterly 
basis by online website application (http://www.medir-
und.nl/). The ADDD have accumulated over time as a 
rolling annual average. An overall warning (benchmark) 
value is assigned annually by the Medicines Authority. 
When this value is exceeded, the farmer is contacted 
by the dairy company and is asked to take appropri-
ate action. Dairy companies are gradually integrating 
antibiotic use indicators into their quality-assurance 
schemes (Kuipers and Verhees, 2011).
Further improvement in responsible drug use can be 
achieved by applying good cow management practices 
and improving herd conditions. This remains an impor-
tant area for research and practical application.
CONCLUSIONS
The indicator ADDD was used to evaluate variation 
and trends in antibiotic use for 3 farmer groups and 
6 treatment categories. Large variation in antibiotic 
use was found between herds, whereas variation in use 
among herds decreased during the study period. In-
creasing drug use awareness was an important external 
factor in reducing antibiotic use and the variation in use. 
Changes in management practices have the potential to 
enhance this effect. Maintenance and restoration of ud-
der health is the main reason for antibiotic use, as 68% 
of all ADDD were used for the udder. A reduction in 
use was achieved mainly due to a reduction in numbers 
of daily dosages used as other treatments. Toward the 
end of the study, a reduction in use for the treatment of 
mastitis was also noted, but farmers remained reluctant 
to reduce dry-cow therapy. The decrease in ADDD over 
time varied between the groups of farmers involved in 
the study. The guided group began to display a reduc-
tion in use at an earlier stage of the study than the 
other 2 groups. Restrictions on the use of third-choice 
drugs were successful in minimizing their use. Corre-
spondingly, a shift toward more use of penicillin and 
certain broad-spectrum drugs was observed. Veterinary 
costs per cow followed the trend in antibiotic use and, 
therefore, decreased in recent years coinciding with the 
downward trend in antibiotic use.
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